Launching Genome Editing: Trials and Triumphs

This chapter explores the early experiences and strategic choices made during the launch of a genome editing program at Intellia Therapeutics. It delves into the emotions of initial patient dosing, the importance of preclinical research, and the calculated risks in delivery methods, reflecting on the company's journey from early models to human trials. The discussion highlights key events, investor skepticism, and the commitment to achieving meaningful therapeutic outcomes in the realm of genetic disease treatment.